Gilead’s newest acquisition: a liver disease drug with $1B in peak sales potential

Gilead’s acquisition of CymaBay Therapeutics underscores the company’s historic success in liver diseases and could bring in $1 billion in peak annual sales.

Gilead announced Monday that it will pay cash to buy CymaBay for $4.3 billion, at $32.50 a share.

CymaBay is developing seladelpar as a second-line treatment for…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks